LAVA Therapeutics N.V. announced the Company will present updated interim data from the dose escalation phase of the ongoing Phase 1/2a clinical trial of LAVA-051 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and virtually June 3-7, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.73 USD | +3.41% | +0.74% | +72.78% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+72.78% | 69.4M | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- LVTX Stock
- News LAVA Therapeutics N.V.
- LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology Annual Meeting